Stuart announces pro-neuronal growth test results for PolyCol

Welcome To Stuart Therapeutics

Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that offers improvements in health outcomes for a wide variety of medical and veterinary conditions.

PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property developed by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.

The initial product under development that takes advantage of PolyCol is ST-100, the first therapeutic for dry eye syndrome that addresses both the immediate painful symptoms, as well as the underlying inflammatory causes.

Indications

Stuart Therapeutics’ first drug candidate is ST-100, a novel therapeutic in drop formulation for Dry Eye Disease (DED). Unlike most therapeutic solutions for DED, ST-100 is a fast acting, broadly applicable option for patients that has shown an ability to provide complete corneal healing in less than 24 hours in animal studies. ST-100 is believed to act by directly healing and aligning exposed and damaged collagen fibers in moderate to severe DED sufferers, providing an ideal environment for epithelial recovery and relief from painful symptoms.

Latest News

11 Nov. 2019
Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides

STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage

Read More
12 Jun. 2019
Stuart Therapeutics, Inc. Announces a Strategic Partnership with Ora, Inc.

STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization.  ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting

Read More
22 Apr. 2019
Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol

April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD). 

Read More